Prucalopride-13C,d3

• UNSPSC Description:

  Prucalopride-13C,d3 is the 13C- and deuterium labeled Prucalopride[1].

• Target Antigen:

  5-HT Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H][13C]([2H])([2H])OCCCN(CC1)CCC1NC(C2=C3C(CCO3)=C(C(Cl)=C2)N)=O

• Molecular Weight:

  371.88

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Bouras EP, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999 May;44(5):682-6.|[3]Briejer MR, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001 Jun 29;423(1):71-83.|[4]Emmanuel AV, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012 Jan;35(1):48-55.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2140306-00-7